Cargando…
Type‐I Interferon assessment in 45 minutes using the FilmArray(®) PCR platform in SARS‐CoV‐2 and other viral infections
Low concentrations of type‐I interferon (IFN) in blood seem to be associated with more severe forms of Coronavirus disease 2019 (COVID‐19). However, following the type‐I interferon response (IR) in early stage disease is a major challenge. We evaluated detection of a molecular interferon signature o...
Autores principales: | Mommert, Marine, Perret, Magali, Hockin, Matthew, Viel, Sébastien, Belot, Alexandre, Richard, Jean‐Christophe, Mezidi, Mehdi, Fassier, Jean‐Baptiste, Javouhey, Etienne, Hemmert, Andrew, Mallet, François, Trouillet‐Assant, Sophie, Brengel‐Pesce, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248375/ https://www.ncbi.nlm.nih.gov/pubmed/33314090 http://dx.doi.org/10.1002/eji.202048978 |
Ejemplares similares
-
Type I IFN immunoprofiling in COVID-19 patients
por: Trouillet-Assant, Sophie, et al.
Publicado: (2020) -
Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021) -
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021) -
Source of Circulating Pentraxin 3 in Septic Shock Patients
por: Albert Vega, Chloé, et al.
Publicado: (2019) -
A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022
por: Guibert, Nicolas, et al.
Publicado: (2023)